Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1221-1227

  Kim, Kyu Pyo ^a   Ahn, Jin Hee ^a   Kim, Sung Bae ^a   Jung, Kyung Hae ^a   Yoon, Dok Hyun ^a   Lee, Jung Shin ^a   Ahn, Sei Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Adjuvant chemotherapy; Breast cancer; Docetaxel; Pharmacogenetics

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; SLCO1B3 PROTEIN, HUMAN; TAXOID;

ABCB1 GENE; ABCC2 GENE; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CYP3A5 GENE; DRUG SAFETY; EDEMA; FEMALE; FLUID RETENTION; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NEUTROPENIA; OPERABLE LYMPH NODE POSITIVE BREAST CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCLO1B3 GENE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN; ADJUVANT CHEMOTHERAPY; ALLELE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; GENETICS; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SOUTH KOREA;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEUTROPENIA; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84862288176     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1816-4     Document Type: Article

References (21)

1. Strother RM, Sweeney C (2008) Lessons learned from development of docetaxel. Expert Opin Drug Metab Toxicol 4(7):1007-1019. doi:10.1517/17425255. 4.7.1007
2. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187-196 (Pubitemid 28041598)
3. Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, Rhodes GR, Rigas JR (2003) Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 9(3):1077-1082 (Pubitemid 36323714)
4. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24(2):153-172 (Pubitemid 26300483)
5. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20(17):3683-3690 (Pubitemid 34983229)
6. Gligorov J, Lotz JP (2004) Preclinical pharmacology of the taxanes: implications of the diVerences. Oncologist 9(Suppl 2):3-8 (Pubitemid 38747838)
7. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev (4):CD004421. doi:10.1002/14651858.CD004421.pub2 (Pubitemid 351805386)
8. Crown J, O'Leary M, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9(Suppl 2):24-32 (Pubitemid 38747840)
9. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, WolV AC, Carducci MA, Sparreboom A (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85(2):155-163. doi:10.1038/clpt.2008.95
10. Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY, Hou MF (2009) Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 404(2):160-165. doi:10.1016/j.cca.2009.03.038
11. Fajac A, Gligorov J, Rezai K, Levy P, Levy E, Selle F, Beerblock K, Avenin D, Saintigny P, Hugonin S, Bernaudin JF, Lokiec F (2010) EVect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer 103(4):560-566. doi:10.1038/sj.bjc. 6605789
12. 2 in advanced nonsmall cell lung cancer patients previously treated with platinumbased chemotherapy. Am J Clin Oncol 26(5):459-464. doi:10.1097/01.coc.0000037736.69148.F9 (Pubitemid 37248261)
13. 2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial. Ann Oncol 20(3):595-596. doi:10.1093/annonc/mdn771
14. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, Kim WS, Heo DS, Kim NK (2002) Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32(7):248-254 (Pubitemid 43102808)
15. EckhoV L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX-a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 50(7):1075-1082. doi:10.3109/0284186X.2011.602111
16. Lin Y, Anderson GD, Kantor E, Ojemann LM, Wilensky AJ (1999) DiVerences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol 39(6):578-582 (Pubitemid 30629037)
17. Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA (2011) Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 17(2):353-362. doi:10.1158/1078-0432.CCR-10-1636
18. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6(7):2598-2603 (Pubitemid 30482093)
19. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99(5):967-972. doi:10.1111/j.1349-7006. 2008.00765.x (Pubitemid 351997599)
20. Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the infiuence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60(2):159-171. doi:10.1111/j.1365-2125.2005. 02392.x (Pubitemid 41075901)
21. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K (2007) Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 64(2):185-191. doi:10.1111/j.1365- 2125.2007.02874.x (Pubitemid 47063248)